VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor a in vivo and in vitro

American Journal of Pathology

Volumn 183, Issue 3, 2013, Pages 918-929

  Beazley Long, Nicholas ^a   Hua, Jing ^a   Jehle, Thomas ^b   Hulse, Richard P ^a   Dersch, Rick ^b   Lehrling, Christina ^b   Bevan, Heather ^a   Qiu, Yan ^a   Lagrèze, Wolf A ^b   Wynick, David ^b   Churchill, Amanda J ^c   Kehoe, Patrick ^a   Harper, Steven J ^a   Bates, David O ^a   Donaldson, Lucy F ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN A165A; VASCULOTROPIN A165B; VASCULOTROPIN RECEPTOR 2; GLUTAMIC ACID; ISOPROTEIN; NEUROPROTECTIVE AGENT; NEUROTOXIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN RECEPTOR 1; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; RETINA ISCHEMIA; RNA SPLICING; SAPHENOUS NERVE; SPINAL GANGLION; ALTERNATIVE RNA SPLICING; ANIMAL; CELL PROTECTION; DRUG EFFECT; GENETICS; HIPPOCAMPUS; METABOLISM; MOUSE; PATHOLOGY; RETINA NERVE CELL; WISTAR RAT; DRUG EFFECTS; TOXICITY;

ALTERNATIVE SPLICING; ANIMALS; CYTOPROTECTION; GANGLIA, SPINAL; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; MALE; MICE; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PROTEIN ISOFORMS; RATS; RATS, WISTAR; RETINAL NEURONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84883166438     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.05.031     Document Type: Article

References (53)

1. Z. Kovacs, K. Ikezaki, K. Samoto, T. Inamura, and M. Fukui VEGF and flt: expression time kinetics in rat brain infarct Stroke 27 1996 1865 1872
2. M.I. Hobson, C.J. Green, and G. Terenghi VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy J Anat 197 pt 4 2000 591 605
3. S.J. Harper, and D.O. Bates VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8 2008 880 887
4. D.O. Bates, T.G. Cui, J.M. Doughty, M. Winkler, M. Sugiono, J.D. Shields, D. Peat, D. Gillatt, and S.J. Harper VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res 62 2002 4123 4131
5. J. Woolard, W.Y. Wang, H.S. Bevan, Y. Qiu, L. Morbidelli, R.O. Pritchard-Jones, T.G. Cui, M. Sugiono, E. Waine, R. Perrin, R. Foster, J. Digby-Bell, J.D. Shields, C.E. Whittles, R.E. Mushens, D.A. Gillatt, M. Ziche, S.J. Harper, and D.O. Bates VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression Cancer Res 64 2004 7822 7835
6. Y. Qiu, J. Ferguson, S. Oltean, C.R. Neal, A. Kaura, H. Bevan, E. Wood, L.M. Sage, S. Lanati, D.G. Nowak, A.H. Salmon, D. Bates, and S.J. Harper Overexpression of VEGF165b in podocytes reduces glomerular permeability J Am Soc Nephrol 21 2010 1498 1509
7. S. Cebe Suarez, M. Pieren, L. Cariolato, S. Arn, U. Hoffmann, A. Bogucki, C. Manlius, J. Wood, and K. Ballmer-Hofer A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2 Cell Mol Life Sci 63 2006 2067 2077
8. P.J. Rosenfeld, D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, C.Y. Chung, and R.Y. Kim Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
9. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
10. E. Storkebaum, D. Lambrechts, and P. Carmeliet VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection Bioessays 26 2004 943 954
11. M. Sondell, G. Lundborg, and M. Kanje Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system J Neurosci 19 1999 5731 5740
12. C.A. Glass, S.J. Harper, and D.O. Bates The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo J Physiol 572 2006 243 257
13. H.S. Bevan, N.M. van den Akker, Y. Qiu, J.A. Polman, R.R. Foster, J. Yem, A. Nishikawa, S.C. Satchell, S.J. Harper, A.C. Gittenberger-de Groot, and D.O. Bates The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development Nephron Physiol 110 2008 57 67
14. A.H. Varey, E.S. Rennel, Y. Qiu, H.S. Bevan, R.M. Perrin, S. Raffy, A.R. Dixon, C. Paraskeva, O. Zaccheo, A.B. Hassan, S.J. Harper, and D.O. Bates VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy Br J Cancer 98 2008 1366 1379
15. S. Harris, M. Craze, J. Newton, M. Fisher, D.T. Shima, G.M. Tozer, and C. Kanthou Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? a cautionary tale PLoS ONE 7 2012 e35231
16. C.R. Elliott-Hunt, B. Marsh, A. Bacon, R. Pope, P. Vanderplank, and D. Wynick Galanin acts as a neuroprotective factor to the hippocampus Proc Natl Acad Sci U S A 101 2004 5105 5110
17. W. Chen, R. Mi, N. Haughey, M. Oz, and A. Hoke Immortalization and characterization of a nociceptive dorsal root ganglion sensory neuronal line J Peripher Nerv Syst 12 2007 121 130
18. F.E. Holmes, S. Mahoney, V.R. King, A. Bacon, N.C. Kerr, V. Pachnis, R. Curtis, J.V. Priestley, and D. Wynick Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity Proc Natl Acad Sci U S A 97 2000 11563 11568
19. I. Selles-Navarro, M.P. Villegas-Perez, M. Salvador-Silva, J.M. Ruiz-Gomez, and M. Vidal-Sanz Retinal ganglion cell death after different transient periods of pressure-induced ischemia and survival intervals: a quantitative in vivo study Invest Ophthalmol Vis Sci 37 1996 2002 2014
20. T. Jehle, K. Wingert, C. Dimitriu, W. Meschede, J. Lasseck, M. Bach, and W.A. Lagreze Quantification of ischemic damage in the rat retina: a comparative study using evoked potentials, electroretinography, and histology Invest Ophthalmol Vis Sci 49 2008 1056 1064
21. A.K. Ahmed, K. Sugioka, K. Dong, and T. Yamadori A study of double-labeled retinal ganglion cells from the superior colliculus in the developing albino rat Brain Res Dev Brain Res 85 1995 71 79
22. T.T. Lam, A.S. Abler, and M.O. Tso Apoptosis and caspases after ischemia-reperfusion injury in rat retina Invest Ophthalmol Vis Sci 40 1999 967 975
23. J.S. Walczak, V. Pichette, F. Leblond, K. Desbiens, and P. Beaulieu Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain Neuroscience 132 2005 1093 1102
24. H. Kawamura, X. Li, S.J. Harper, D.O. Bates, and L. Claesson-Welsh Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity Cancer Res 68 2008 4683 4692
25. H. Matsuzaki, M. Tamatani, A. Yamaguchi, K. Namikawa, H. Kiyama, M.P. Vitek, N. Mitsuda, and M. Tohyama Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades FASEB J 15 2001 1218 1220
26. J.M. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O'Reilly, E. Persohn, J. Rosel, C. Schnell, D. Stover, A. Theuer, H. Towbin, F. Wenger, K. Woods-Cook, A. Menrad, G. Siemeister, M. Schirner, K.H. Thierauch, M.R. Schneider, J. Drevs, G. Martiny-Baron, and F. Totzke PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2000 2178 2189
27. C.E. Whittles, T.M. Pocock, S.R. Wedge, J. Kendrew, L.F. Hennequin, S.J. Harper, and D.O. Bates ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity Microcirculation 9 2002 513 522
28. E. Gomes, L. Papa, T. Hao, and P. Rockwell The VEGFR2 and PKA pathways converge at MEK/ERK1/2 to promote survival in serum deprived neuronal cells Mol Cell Biochem 305 2007 179 190
29. D. Lambrechts, E. Storkebaum, M. Morimoto, J. Del-Favero, F. Desmet, S.L. Marklund, S. Wyns, V. Thijs, J. Andersson, I. van Marion, A. Al-Chalabi, S. Bornes, R. Musson, V. Hansen, L. Beckman, R. Adolfsson, H.S. Pall, H. Prats, S. Vermeire, P. Rutgeerts, S. Katayama, T. Awata, N. Leigh, L. Lang-Lazdunski, M. Dewerchin, C. Shaw, L. Moons, R. Vlietinck, K.E. Morrison, W. Robberecht, C. Van Broeckhoven, D. Collen, P.M. Andersen, and P. Carmeliet VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death Nat Genet 34 2003 383 394
30. R. Hulse, D. Wynick, and L.F. Donaldson Characterization of a novel neuropathic pain model in mice Neuroreport 19 2008 825 829
31. B. Oosthuyse, L. Moons, E. Storkebaum, H. Beck, D. Nuyens, K. Brusselmans, J. Van Dorpe, P. Hellings, M. Gorselink, S. Heymans, G. Theilmeier, M. Dewerchin, V. Laudenbach, P. Vermylen, H. Raat, T. Acker, V. Vleminckx, L. Van Den Bosch, N. Cashman, H. Fujisawa, M.R. Drost, R. Sciot, F. Bruyninckx, D.J. Hicklin, C. Ince, P. Gressens, F. Lupu, K.H. Plate, W. Robberecht, J.M. Herbert, D. Collen, and P. Carmeliet Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration Nat Genet 28 2001 131 138
32. I. Zachary Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential Neurosignals 14 2005 207 221
33. K.L. Jin, X.O. Mao, and D.A. Greenberg Vascular endothelial growth factor rescues HN33 neural cells from death induced by serum withdrawal J Mol Neurosci 14 2000 197 203
34. K.L. Jin, X.O. Mao, and D.A. Greenberg Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia Proc Natl Acad Sci U S A 97 2000 10242 10247
35. J.N. Nicoletti, S.K. Shah, D.P. McCloskey, J.H. Goodman, A. Elkady, H. Atassi, D. Hylton, J.S. Rudge, H.E. Scharfman, and S.D. Croll Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus Neuroscience 151 2008 232 241
36. J.M. Rosenstein, N. Mani, A. Khaibullina, and J.M. Krum Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons J Neurosci 23 2003 11036 11044
37. H. Kawamura, X. Li, K. Goishi, L.A. van Meeteren, L. Jakobsson, S. Cebe-Suarez, A. Shimizu, D. Edholm, K. Ballmer-Hofer, L. Kjellen, M. Klagsbrun, and L. Claesson-Welsh Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization Blood 112 9 2008 3638 3640
38. K. Nishijima, Y.S. Ng, L. Zhong, J. Bradley, W. Schubert, N. Jo, J. Akita, S.J. Samuelsson, G.S. Robinson, A.P. Adamis, and D.T. Shima Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am J Pathol 171 2007 53 67
39. H. Kawamura, X. Li, K. Goishi, L.A. van Meeteren, L. Jakobsson, S. Cebe-Suarez, A. Shimizu, D. Edholm, K. Ballmer-Hofer, L. Kjellen, M. Klagsbrun, and L. Claesson-Welsh Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization Blood 112 2008 3638 3649
40. M. Almasieh, A.M. Wilson, B. Morquette, J.L. Cueva Vargas, and A. Di Polo The molecular basis of retinal ganglion cell death in glaucoma Prog Retin Eye Res 31 2012 152 181
41. A.L. Magnussen, E.S. Rennel, J. Hua, H.S. Bevan, N. Beazley Long, C. Lehrling, M. Gammons, J. Floege, S.J. Harper, H.T. Agostini, D.O. Bates, and A.J. Churchill VEGF-A165b is cytoprotective and antiangiogenic in the retina Invest Ophthalmol Vis Sci 51 2010 4273 4281
42. J. Hua, C. Spee, S. Kase, E.S. Rennel, A.L. Magnussen, Y. Qiu, A. Varey, S. Dhayade, A.J. Churchill, S.J. Harper, D.O. Bates, and D.R. Hinton Recombinant human VEGF165b inhibits experimental choroidal neovascularization Invest Ophthalmol Vis Sci 51 2010 4282 4288
43. G. Lin, A.W. Shindel, T.M. Fandel, A.J. Bella, C.S. Lin, and T.F. Lue Neurotrophic effects of brain-derived neurotrophic factor and vascular endothelial growth factor in major pelvic ganglia of young and aged rats BJU Int 105 2010 114 120
44. M. Sondell, and M. Kanje Postnatal expression of VEGF and its receptor flk-1 in peripheral ganglia Neuroreport 12 2001 105 108
45. T. Licht, I. Goshen, A. Avital, T. Kreisel, S. Zubedat, R. Eavri, M. Segal, R. Yirmiya, and E. Keshet Reversible modulations of neuronal plasticity by VEGF Proc Natl Acad Sci U S A 108 2011 5081 5086
46. R.O. Pritchard-Jones, D.B. Dunn, Y. Qiu, A.H. Varey, A. Orlando, H. Rigby, S.J. Harper, and D.O. Bates Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma Br J Cancer 97 2007 223 230
47. E. Rennel, E. Waine, H. Guan, Y. Schuler, W. Leenders, J. Woolard, M. Sugiono, D. Gillatt, E. Kleinerman, D. Bates, and S. Harper The endogenous anti-angiogenic VEGF isoform. VEGF165b inhibits human tumour growth in mice Br J Cancer 98 2008 1250 1257
48. E.S. Rennel, M.A. Hamdollah-Zadeh, E.R. Wheatley, A. Magnussen, Y. Schuler, S.P. Kelly, C. Finucane, D. Ellison, S. Cebe-Suarez, K. Ballmer-Hofer, S. Mather, L. Stewart, D.O. Bates, and S.J. Harper Recombinant human VEGF165b protein is an effective anti-cancer agent in mice Eur J Cancer 44 2008 1883 1894
49. P. Schratzberger, G. Schratzberger, M. Silver, C. Curry, M. Kearney, M. Magner, J. Alroy, L.S. Adelman, D.H. Weinberg, A.H. Ropper, and J.M. Isner Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy Nat Med 6 2000 405 413
50. P. Schratzberger, D.H. Walter, K. Rittig, F.H. Bahlmann, R. Pola, C. Curry, M. Silver, J.G. Krainin, D.H. Weinberg, A.H. Ropper, and J.M. Isner Reversal of experimental diabetic neuropathy by VEGF gene transfer J Clin Invest 107 2001 1083 1092
51. T. Yasuhara, T. Shingo, K. Muraoka, M. Kameda, T. Agari, Y. Wen Ji, H. Hayase, H. Hamada, C.V. Borlongan, and I. Date Neurorescue effects of VEGF on a rat model of Parkinson's disease Brain Res 1053 2005 10 18
52. A.H. Ropper, K.C. Gorson, C.L. Gooch, D.H. Weinberg, A. Pieczek, J.H. Ware, J. Kershen, A. Rogers, D. Simovic, P. Schratzberger, R. Kirchmair, and D. Losordo Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial Ann Neurol 65 2009 386 393
53. R.R. Foster, R. Hole, K. Anderson, S.C. Satchell, R.J. Coward, P.W. Mathieson, D.A. Gillatt, M.A. Saleem, D.O. Bates, and S.J. Harper Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes Am J Physiol Renal Physiol 284 2003 F1263 F1273